Myoclonic Epilepsy
Symptoms, Doctors, Treatments, Advances & More

Myoclonic Epilepsy Overview

Save information for later
Sign Up

Learn About Myoclonic Epilepsy

What is the definition of Myoclonic Epilepsy?
Myoclonic epilepsy is a type of seizure disorder characterized by quick jerking movements due to uncontrolled muscle contractions caused by abnormal electrical impulses in the brain. Unlike grand mal (tonic-clonic) seizures, during a myoclonic seizure the affected individual does not lose consciousness. There are several types of myoclonic epilepsy, including infantile spasms, Lennox-Gastaut Syndrome, juvenile myoclonic epilepsy, and progressive myoclonic epilepsy, among others.
What are the symptoms of Myoclonic Epilepsy?
Symptoms of myoclonic epilepsy depend on the type and usually affects the neck, shoulders, and upper arms. Symptoms of myoclonic epilepsy may include quick, uncontrolled muscle jerks; rhythmic movements; arms flinging outward; knees pulling up; body stiffening; and unusual clumsiness. Myoclonic seizures may occur with atonic seizures, which cause limp muscles. When myoclonic epilepsy worsens, it is known as progressive myoclonic epilepsy, which is a rare seizure disorder characterized by both myoclonic and tonic-clonic (grand mal) seizures.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Myoclonic Epilepsy?
Treatment for myoclonic epilepsy depends on the type, frequency, and severity of the seizures and may include anti-seizure (anti-epileptic) medications, ketogenic diet, vagus nerve stimulator (VNS) implantation, and surgery.
Who are the top Myoclonic Epilepsy Local Doctors?
Elite in Myoclonic Epilepsy
Dr. Jack Parent
Neurology
Elite in Myoclonic Epilepsy
Dr. Jack Parent
Neurology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
734-936-9020
Languages Spoken:
English
See accepted insurances

Jack Parent is a Neurologist in Ann Arbor, Michigan. Dr. Parent is rated as an Elite provider by MediFind in the treatment of Myoclonic Epilepsy. His top areas of expertise are Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome.

Javier A. Echeverri
Distinguished in Myoclonic Epilepsy
Dr. Javier A. Echeverri
Neurology
Distinguished in Myoclonic Epilepsy
Dr. Javier A. Echeverri
Neurology

St. Vincent Neurosurgery

1041 North 29th Street, 
Billings, MT 
406-237-5577
Experience:
47+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Javier Echeverri is a Neurologist in Billings, Montana. Dr. Echeverri has been practicing medicine for over 47 years and is rated as a Distinguished provider by MediFind in the treatment of Myoclonic Epilepsy. His top areas of expertise are Essential Tremor, Parkinson's Disease, Movement Disorders, Epilepsy with Myoclonic-Atonic Seizures, and Deep Brain Stimulation. Dr. Echeverri is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Jyoti A. Pillai
Advanced in Myoclonic Epilepsy
Dr. Jyoti A. Pillai
Neurology
Advanced in Myoclonic Epilepsy
Dr. Jyoti A. Pillai
Neurology

Reading Hospital Neurology Suite 3020

301 S 7th Ave, Ste 3020, 
West Reading, PA 
484-628-4656
Languages Spoken:
English
See accepted insurances

. Dr. Pillai is rated as an Advanced provider by MediFind in the treatment of Myoclonic Epilepsy. Her top areas of expertise are Seizures, Epilepsy, Memory Loss, and Generalized Tonic-Clonic Seizure.

View All Doctors
What are the latest Myoclonic Epilepsy Clinical Trials?
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3

Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

View All Clinical Trials